Summary
Johnson & Johnson (JNJ) has filed an 8-K report on January 21, 2026, to announce its financial results for the fourth quarter and full year ended December 28, 2025. The filing primarily directs investors to a press release (Exhibit 99.1) and supplementary data (Exhibit 99.2) for detailed sales and earnings information. While the 8-K itself does not contain the specific figures, these attached exhibits are the primary source for understanding the company's performance during the reported periods, including key financial metrics and operational achievements.
Key Highlights
- 1JNJ announced fourth quarter and full year 2025 financial results.
- 2The results cover the period ended December 28, 2025.
- 3Detailed financial information is provided in an attached press release (Exhibit 99.1).
- 4Unaudited comparative supplementary sales data and condensed consolidated statements of earnings are also available (Exhibit 99.2).
- 5This report serves as the official notification of the company's financial performance for the specified periods.
- 6Investors are directed to these exhibits for specific sales and earnings figures.
Frequently Asked Questions
The specific sales and earnings numbers are detailed in the press release dated January 21, 2026 (Exhibit 99.1) and the unaudited comparative supplementary sales data and condensed consolidated statement of earnings (Exhibit 99.2) attached to this 8-K filing.
The financial results announced in this 8-K filing cover the fourth quarter and the full fiscal year ended December 28, 2025.
This 8-K filing primarily serves to announce and provide access to the company's financial results for the fourth quarter and full year 2025. The detailed operational and financial performance information is contained within the attached exhibits, specifically the press release and supplementary data.